Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia
Shots: The EMA has granted PRIME designation to NX-5948 for adults with r/r chroni...
UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)
Shots: The US FDA has granted approval to Bimzelx (IL-17F & IL-17A inhibitor)...
Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary...
Shots: The US FDA’s accelerated approval of Ziihera (50mg/mL, IV) was based...
Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy
Shots: The US FDA has cleared IND application of ST-503 to initiate its P-I/II cli...
Pfizer Reports the EC’s Approval of Hympavzi (Marstacimab) to Treat Hemophilia A/B without Inhibitors in Adults and Adolescents
Shots: The EC has approved Hympavzi (QW, SC) as a prophylactic treatment to preven...
AstraZeneca Reports the CHMP’s Positive Opinion of Tagrisso (Osimertinib) for Treating Unresectable EGFR-Mutated Lung Cancer
Shots: The CHMP has issued positive opinion for Tagrisso as a treatment of locally...
